Amesite Inc.

Amesite is headquartered in the United States and its filings are written as those of a U.S. public company. The available excerpts do not disclose a formal geographic revenue split, and the business appears to be primarily U.S.-focused based on its healthcare and education customer base. Because NurseMagic™ targets regulated U.S. healthcare settings, domestic compliance requirements such as HIPAA and CMS rules are central to operations. The company also references GDPR in its risk disclosures, indicating that privacy and data rules outside the U.S. could matter if it expands internationally or handles cross-border data. At present, geography matters more as a regulatory and market-access issue than as a manufacturing or supply-chain footprint.

Amesite faces substantial execution risk because it is still building a recurring revenue base while competing against larger healthcare software vendors and AI-first entrants. Its NurseMagic™ product operates in a heavily regulated environment, so failures in HIPAA, CMS, privacy, or emerging AI compliance could trigger penalties, customer loss, or reputational damage. The company also depends on adoption by nurses and healthcare organizations, and market acceptance could be slowed by organizational inertia, integration concerns, or skepticism about AI in clinical settings. Financially, the business remains unprofitable and has disclosed substantial doubt about its ability to continue as a going concern, making access to external financing a key risk. More broadly, macro weakness in healthcare IT spending, cybersecurity incidents, and rapid changes in AI regulation could all pressure growth and operating continuity.